Using next-generation sequencing, the UPSeq test assesses 15 biomarkers to find aggressive prostate cancer that can be missed by biopsies or imaging tests.

The new approach blocks the interaction between cancer cells and immune receptors, showing promise in mice.

Urine test found to be extremely accurate at detecting aggressive prostate cancer with few false negatives.

Clinical trials underway are testing whether drugs that target the androgen receptor – successful in controlling prostate cancer – could also work against the coronavirus.

The multi-institution phase 1b/2a clinical trial found good tolerability and encouraging efficacy data for the pan-BET bromodomain inhibitor in combination with enzalutamide.

Multi-institution analysis identifies a new chromosomal abnormality linked to enzalutamide resistance.